Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T · 1 trial · 2 indications
Determine if treatment with autologous genetically modified T cells, (MAGE A10ᶜ⁷⁹⁶T ) is safe and tolerable through assessment of DLTs, AEs, including SAEs; laboratory assessments, including chemistry, hematology, and coagulation; cardiac and pulmonary assessments, including ECG and troponin.
| Arm | Type | Description |
|---|---|---|
| Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T | BIOLOGICAL | - |
Key Inclusion Criteria: 1. Subject has histologically or cytologically confirmed diagnosis of advanced non-small cell lung cancer (stage IIIB or IV) or recurrent disease 2. Subject has received at least one line of prior therapy 3. Subjects with known epidermal growth factor receptor (EGFR) mutatio...
Top 20 of 79 competitors
Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T is being studied for the treatment of non-small cell lung cancer (NSCLC). It is an investigational therapy being developed by Adaptimmune Therapeutics PLC (ticker: ADAP). The therapy is designed for patients with advanced NSCLC whose tumors express the MAGE-A10 antigen, as it is a biomarker-selected treatment.
Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T targets the MAGE-A10 antigen, which is a cancer-testis antigen expressed in certain tumors. The target class is an exogenous gene, meaning the T cells are genetically modified to express a T-cell receptor that recognizes MAGE-A10. This allows the modified T cells to specifically attack cancer cells presenting the MAGE-A10 antigen.
Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T is being developed by Adaptimmune Therapeutics PLC, which trades on the Nasdaq under the ticker ADAP. Adaptimmune is a clinical-stage biopharmaceutical company focused on T-cell therapies for cancer.
Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T is in Phase 1 clinical development. The only trial conducted for this therapy was a Phase 1 study that has been completed. As a Phase 1 investigational therapy, it has not been approved by the FDA for any indication.
Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T has been evaluated in one clinical trial: NCT02592577, titled "MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC." This Phase 1 trial enrolled 28 patients with non-small cell lung cancer and was conducted in the United States, Canada, Spain, and the United Kingdom. The trial is now completed.